Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164686 | 0.91 | CCNA2 (0.39) | CCNA2CDK2F10CCNB2CDK1 | |
| SCHEMBL1164761 | 0.88 | CCNA2 (0.39) | CCNA2CDK2 | |
| SCHEMBL12785107 | 0.83 | CCNA2 (0.39) | CCNA2CDK2F10 | |
| SCHEMBL12785109 | 0.79 | CCNA2 (0.39) | CCNA2CDK2 | |
| SCHEMBL2071643 | 0.78 | CDK2 (0.41) | CCNA2CDK2CDK1 | |
| SCHEMBL16001674 | 0.78 | CCNA2 (0.40) | CCNA2CDK2 | |
| SCHEMBL1164895 | 0.75 | CCNA2 (0.38) | CCNA2CDK2 | |
| SCHEMBL1163867 | 0.72 | CCNA2 (0.60) | CCNA2CDK2 | |
| SCHEMBL1164010 | 0.72 | CCNA2 (0.39) | CCNA2CDK2 | |
| SCHEMBL12784003 | 0.72 | CCNA2 (0.71) | CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885F10 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.